#alfasigma
LightNews LightNews
wsj.com
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat. on.wsj.com/4cCOMO4
GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
on.wsj.com
March 9, 2026 at 7:41 AM
rubensanchez.tw
Erupciones cutáneas o angioedema: alertan de posibles reacciones adversas en un lote del complemento alimenticio Yovis Kids
facua.org/noticias/eru...
Erupciones cutáneas o angioedema: alertan de posibles reacciones adversas en un lote del complemento alimenticio Yovis Kids
Está afectado el lote N03387 de este probiótico para menores comercializado por Alfasigma.
facua.org
May 15, 2025 at 8:21 AM
wsj.com
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat. on.wsj.com/4sw41wJ
GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.
on.wsj.com
March 9, 2026 at 7:44 AM
facua.org
Erupciones cutáneas o angioedema: alertan de posibles reacciones adversas en un lote del complemento alimenticio Yovis Kids
Erupciones cutáneas o angioedema: alertan de posibles reacciones adversas en un lote del complemento alimenticio Yovis Kids
Está afectado el lote N03387 de este probiótico para menores comercializado por Alfasigma.
facua.org
May 15, 2025 at 9:02 AM
georgprice.bsky.social
Alfasigma!
December 11, 2024 at 7:59 PM
eib.org
We are granting €150 million loan to Alfasigma, a global pharmaceutical company, to boost R&D in rare diseases and specialty care.

The financing will accelerate innovation in gastroenterology, hepatology, vascular medicine and rheumatology.

➡️ bit.ly/45Z644v
July 8, 2025 at 10:27 AM
biobonanos.bsky.social
Missed this one early today: CRL for Ocaliva obeticholic acid from Intercept Pharmaceuticals, now owned by Italian pharma Alfasigma S.p.A. following an $800m buyout. No full approval in primary biliary cholangitis; Intercept also got two CRLs in NASH/MASH. www.globenewswire.com/news-release...
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A.,...
www.globenewswire.com
November 12, 2024 at 6:26 PM
longtail-news.bsky.social
Feed: "Business-News-Today.com"
By: Venkatesh on Monday, March 9, 2026
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
business-news-today.com
March 10, 2026 at 12:14 AM
diarionutricion.com
Los datos del producto implicado son: Yovis Kids, nombre de marca comercial: Alfasigma, en envase con 10 viales, número de lote: N03387, fecha de caducidad: 01/04/2026 y CN 214347.0
Alerta por posible reacción adversa por complemento alimenticio de Alfasigma destinado a niños
La Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) informa de la retirada del producto Yovis Kids, comercializado como complemento alimenticio, por poder producir reacciones ad ...
bit.ly
April 18, 2025 at 10:02 AM
diarionutricion.com
La Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) informa de la retirada del producto Yovis Kids de #Alfasigma, comercializado como complemento alimenticio, por poder producir reacciones adversas de diversa gravedad
Alerta por posible reacción adversa por complemento alimenticio de Alfasigma destinado a niños
La Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) informa de la retirada del producto Yovis Kids, comercializado como complemento alimenticio, por poder producir reacciones ad ...
bit.ly
April 16, 2025 at 1:31 PM
salutedomani.bsky.social
Alfasigma acquisisce Nordic Group B.V. ed espande la sua presenza in Europa e il suo portfolio specialty care

Alfasigma S.p.A., azienda farmaceutica globale, ha annunciato oggi di aver firmato un accordo con SEVER Life Sciences B.V. ("SEVER") per la vendita del 100% delle azioni di Nordic Group…
Alfasigma acquisisce Nordic Group B.V. ed espande la sua presenza in Europa e il suo portfolio specialty care
Alfasigma S.p.A., azienda farmaceutica globale, ha annunciato oggi di aver firmato un accordo con SEVER Life Sciences B.V. ("SEVER") per la vendita del 100% delle azioni di Nordic Group B.V e delle sue controllate (Nordic Pharma). Nordic Pharma è un'azienda farmaceutica a capitale privato con strutture operative in Europa, Canada e Giappone. L’operazione consentirà ad Alfasigma di integrare nel proprio portfolio di reumatologia – che include il franchise Jyseleca® – il business di Nordic Pharma nel trattamento dell’artrite reumatoide, e in particolare il franchise del metotrexato Nordimet®.
www.saluteh24.com
August 11, 2026 at 6:37 PM
marketwire.bsky.social
💵 #Forex

"Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise.…"
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe
financialpost.com
August 11, 2026 at 12:29 PM
qnazionale.bsky.social
Farmaceutica, da Alfasigma un nuovo piano di investimenti per il polo di Pomezia
dlvr.it
July 20, 2026 at 12:50 PM
diarionutricion.com
Alerta por posible reacción adversa por complemento alimenticio de Alfasigma destinado a niños
Alerta por posible reacción adversa por complemento alimenticio de Alfasigma destinado a niños
La Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) informa de la retirada del producto Yovis Kids, comercializado como complemento alimenticio, por poder producir reacciones ad ...
www.diarionutricion.com
April 17, 2025 at 9:02 AM
accuespana.bsky.social
Gracias también a GETECCU, GETEII, ACCU Aragón y POP por acompañarnos en este camino

Gracias al Ministerio de Derechos Sociales, Consumo y Agenda 2030, junto a AbbVie, Alfasigma, Biogen, GSK, Lilly y Takeda por su apoyo

#SomosUno
July 1, 2026 at 1:24 PM
openpharma.bsky.social
📢 Read this wseek’s #OpenScience news here! 📢

Sign up to our blog to receive your weekly news digest and more straight to your inbox!

#OpenAccess #PublicationEthics @orcid.org @doaj.bsky.social

www.openpharma.blog/blog/news/we...
Weekly digest: Publication Integrity Week, ORCID funding and Alfasigma OA mandate
This week, we look ahead to COPE Publication Integrity Week 2025 and amplify the launch of the 2025 ORCID Global Participation Fund. We also celebrate the launch of Open Pharma Member Alfasigma’s new ...
www.openpharma.blog
October 27, 2025 at 3:22 PM
openpharma.bsky.social
📢 Read this week’s #OpenScience news here! 📢

Sign up to our blog to receive your weekly news digest and more straight to your inbox!

#ArtificalIntelligence #AI #PubMed #PredatoryPublishers #OpenAccess

www.openpharma.blog/blog/transpa...
Weekly digest: AI-written papers, a PubMed alternative and retracted research
This week, we welcome Alfasigma to Open Pharma and highlight 10 must-reads for transparent and reproducible pharmacoepidemiology research. We read about Springer Nature’s donation of a tool to spot AI...
www.openpharma.blog
May 23, 2025 at 11:05 AM
openpharma.bsky.social
🎉 Alfasigma becomes the newest Member of Open Pharma!

Read the full press release on our blog ⤵️
#OpenPharma #OpenScience #PharmaceuticalsWithPassion #Welcome #Pharma
www.openpharma.blog/blog/news/al...
Alfasigma becomes a Member of Open Pharma
Open Pharma is proud to announce that Alfasigma has become the latest Member of Open Pharma.
www.openpharma.blog
May 19, 2025 at 2:05 PM
openpharma.bsky.social
🚀 Join Open Pharma at the 2025 #EMWASpringConference! 🚀

Let's work together to make #ScientificResearch more #Accessible and #Understandable for everyone! 🌍
EMWA Spring Conference Riga, Latvia 6–9 May 2025 Join our roundtable titled 'Cross-publisher plain language article guidance: have your say' on 8 May at 07:45–08:30 EEST with Sarah Griffiths, Communications Director at Oxford PharmaGenesis Join author Slavka Baronikova (Senior Director at Alfasigma) as she presents our poster titled 'Use of plain language summaries by healthcare professionals: an Open Pharma survey' #EMWASpringConference
May 7, 2025 at 10:55 AM
zimmermanv66.bsky.social
search.app/RkHRS
GSK licenses liver disease drug to Italy's Alfasigma for up to $690 million
GSK said on Monday it ‌will receive up to $690 million from Italian pharmaceutical company Alfasigma for the worldwide ​rights to linerixibat, an experimental treatment ​for severe itching in patients...
search.app
March 9, 2026 at 2:15 PM
pressreleasecc.com
Gastroparesis Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma
www.pressreleasecc.com
June 27, 2026 at 6:45 AM
pressreleasecc.com
Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight

Sickle Cell Disease Drugs Market Sickle Cell Disease companies working in the treatment market are Cellectis, Sana…
Sickle Cell Disease Drugs Market 2034: Clinical Trials, Prevalence, EMA, PDMA, FDA Approvals, Medication, Statistics, NICE Approval.Revenue and Companies by DelveInsight
Sickle Cell Disease Drugs Market Sickle Cell Disease companies working in the treatment market are Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others. Sickle Cell Disease Market Summary In 2023, the Sickle Cell Disease (SCD) market across the 6MM was valued at approximately USD 650 million, with the United States dominating at ~USD 603 million (92% share), followed by France and the UK.
www.pressreleasecc.com
July 7, 2025 at 11:01 AM